DRMA.US Dermata Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.6212 USD
Close of Nov 14, 2026
0.5707 3.16
Market cap
USD 3.06M
P/E
-
P/B
0.93x
ROE
-260.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DRMA.US undervalued?

Graham number

The Graham number of Dermata Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dermata Therapeutics Inc fundamental analysis

No fundamental analysis for Dermata Therapeutics Inc yet.

Dermata Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dermata Therapeutics Inc

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Full company profile